Table II.
Current trials involving immune checkpoint inhibitors for the treatment of large cell neuroendocrine carcinoma.
| Trial | Phase | Tumors | n | Experimental arm | Primary endpoint | Status |
|---|---|---|---|---|---|---|
| NCT05470595 (LCNEC-ALPINE) | II | Locally advanced or metastatic LCNEC | 67 | Atezolizumab | OS | Recruiting |
| NCT03591731 (NIPINEC) | II | Gastroenteropancreatic or pulmonary poorly differentiated neuroendocrine tumors (including LCNEC) | 185 | Arm A: Nivolumab; Arm B: Nivolumab + ipilimumab | ORR | Active, not recruiting |
| NCT03976518 (CHANCE) | II | Advanced non-small cell lung cancer with rare histologies (including LCNEC) | 43 | Atezolizuma b | DCR | Recruiting |
| NCT03728361 | II | Small cell lung cancer or advanced neuroendocrine cancer (including LCNEC) | 55 | Nivolumab + temozolomide | ORR | Active, not recruiting |
| EudraCT 2020-005942-41 (DUPLE) | II | Metastatic LCNEC | 49 | Durvalumab with carboplatin + etoposide followed by durvalumab maintenance | OS rate at 1 year | Ongoing |
| EudraCT 2020-002683-31 | II | Advanced LCNEC | 67 | Atezolizumab with platinum + etoposide | OS | Ongoing |
| ChiCTR 2300068111 | II | Locally advanced/metastatic LCNEC | 64 | Serplulimab with carboplatin + etoposide | ORR | Prospective registration |
LCNEC, large cell neuroendocrine carcinoma; OS, overall survival; ORR, objective response rate; DCR, disease control rat.